Transgene News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

10.06.14	Transgene Announces Participation in Upcoming Investor Events in France and US (Businesswire)
27.05.14	Transgene Announces Promising Results in an Update from the Phase 2b Part of TIME Trial with TG4010 in Advanced Non-Small Cell Lung Cancer (Businesswire)
12.05.14	Transgene Announces Presentations at Upcoming Investor Conferences (Businesswire)
28.04.14	Transgene Announces Option for TG4010 Not Exercised (Businesswire)
22.04.14	Transgene Reports First Quarter 2014 Financial Results (Businesswire)
26.03.14	Transgene Reports Fiscal Year 2013 Results and Provides Business Update (Businesswire)
26.03.14	Global Partners SillaJen, Transgene and Lee’s Pharmaceutical Confirm Clinical Development Plan for Pexa-Vec (Businesswire)
25.03.14	Transgene Schedules Conference Call to Discuss 2013 Financial Results (Businesswire)
25.03.14	Transgene Successfully Completes Rights Issue and Private Placement (Businesswire)
18.03.14	Transgene Reports that the Acquisition of Jennerex, Inc. by SillaJen has Closed (Businesswire)
03.03.14	CORRECTING and REPLACING: Transgene Launches a Rights Issue of €45.5 Million Euros at a Price of 10 Euros Per Share (Businesswire)
28.02.14	Transgene launches a rights issue of €45.5 million euros at a price of 10 euros per share (Businesswire)
25.02.14	Transgene Announces Plans for a Phase 1b/2 Trial with Pexa-Vec in Advanced Solid Tumors (Businesswire)
29.01.14	Sanofi and Transgene Launch Construction Phase of New State-of-the-art Bioproduction Platform (Businesswire)
08.01.14	Transgene Announces Topline Preliminary Results from Phase 2b Part of TIME Trial with TG4010 in Non-Small Cell Lung Cancer (Businesswire)
26.11.13	Transgene Supports Proposed Acquisition of Jennerex by SillaJen (Businesswire)
05.11.13	Transgene Announces Data on TG1050 Presented at Recent Medical and Scientific Conferences (Businesswire)
04.11.13	Transgene Provides Update on Timing of Upcoming Milestone for TG4010 (Businesswire)
30.10.13	Transgene in Collaboration with Emergent BioSolutions to Receive NIH Funding to Support Development of a Novel Immunotherapy against Tuberculosis (Businesswire)
29.10.13	Transgene Announces Presentations at Upcoming Investor Conferences (Businesswire)
21.10.13	Transgene Announces Third Quarter 2013 Financial Results (Businesswire)
12.09.13	Transgene Reports 2013 Half Year Results (Businesswire)
03.09.13	Transgene Announces that its Phase 2 study of Pexa-Vec in Second-line Advanced Liver Cancer did not Meet its Primary Endpoint (Businesswire)
03.07.13	Transgene Grants Ascend Biopharmaceuticals a License to TG1042, an Immunotherapy to Treat Basal Cell Carcinoma, a Common Type of Skin Cancer (Businesswire)
16.01.13	Transgene Announces its Financial Calendar for 2013 (Businesswire)
13.11.12	Transgene to Collaborate with the EORTC on a Phase 2b Trial with TG4001 in Head and Neck Cancer (Businesswire)
18.10.12	Transgene: Third Quarter 2012 Financial Report (Businesswire)
20.09.12	Transgene Announces the Recruitment of Dr. Nathalie Adda as Chief Medical Officer (Businesswire)
17.09.12	Jennerex and Transgene Present Positive Clinical Data from Phase 2 Trial of JX594/TG6006 in Sorafenib-Refractory Liver Cancer Patients (Businesswire)
11.09.12	Transgene Reports 2012 Half Year Results (Businesswire)
27.07.12	Start of Operations in the 50:50 Chinese Joint Venture Between Tasly Pharmaceutical Group Co., Ltd. and Transgene (Businesswire)
25.07.12	Jennerex and Transgene Announce First Patient Treated In Phase 2 Clinical Trial of Intravenous Delivery of JX594/TG6006 In Patients with Advanced Liver Cancer (Businesswire)
17.05.12	Transgene Announces Presentations Relating to TG4010 and JX594/TG6006 at Annual Meeting of the American Society of Clinical Oncology (ASCO) (Businesswire)
09.05.12	Transgene Reports Randomized Phase 2b Data with Its Therapeutic HPV Vaccine TG4001 in Women with CIN2/3 Intraepithelial Cervical Neoplasia (Businesswire)
23.04.12	Transgene Reports Positive Follow Up Phase 2 Data on Its HCV Therapeutic Vaccine TG4040 (Businesswire)
19.04.12	Transgene : First Quarter 2012 Financial Report (Businesswire)
19.04.12	Transgene’s New Therapeutic Vaccine Candidate (TG1050) to Treat Chronic Hepatitis B ("CHB”) Reaches Pre-Clinical Proof of Concept (Businesswire)
20.03.12	Transgene and Jennerex Announce First Patient Treated in Phase 1/2 Clinical Trial of JX594/TG6006 in Combination with Chemotherapy in Patients with Metastatic Colorectal Cancer (Businesswire)
19.03.12	Transgene Reports Full Year 2011 Results (Businesswire)
30.01.12	Transgene Creates a Subsidiary in China and signs Immunocan, a European Commission Subsidized International Scientific Cooperation Program, with Chinese and European Academic Laboratories (Businesswire)
21.12.11	Transgene and Jennerex Announce First Patient Treated in Phase 2a Clinical Trial of JX594/TG6006 in Colorectal Cancer Patients (Businesswire)
16.12.11	Transgene and the French League Against Cancer Enter Partnership to Accelerate Research and Development of New Anticancer Biotherapies (Businesswire)
07.11.11	Transgene’s Therapeutic HCV Vaccine TG4040 Combined with Commonly Used Treatment Achieves Substantial Viral Suppression in Randomized Phase II Trial (Businesswire)
07.11.11	Transgene and Jennerex Announce Final Data at AASLD From JX594/TG6006 Randomized Phase 2 Clinical Trial Showing Statistically Significant Survival Benefit in Patients with Advanced Liver Cancer (Businesswire)
04.05.11	The Pell Institute and DeVry Inc. Announce Live Webcast of Education Policy Forum to Take Place May 11 (Businesswire)
05.04.11	Acme Packet Session Border Controllers Secure Alcatel-Lucent Communications Solutions for Enterprises (Businesswire)
16.12.10	Jennerex and Transgene Announce Initiation of Clinical Trial of Intravenous JX-594 in Patients with Refractory Metastatic Colorectal Cancer (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Transgene S.A.

Aktien Top/Flop

Meistgelesene Nachrichten